drug_type
RELEVANT_DRUG
intervention_type
Biological (Cellular therapy; CAR-NK)
drug_description
An off-the-shelf, allogeneic NK-92–derived CAR-NK cell therapy engineered to express an anti-CD19 CAR for direct killing of CD19+ B cells, secrete ER-retained IL-2 to support NK activation/persistence, and express high-affinity CD16a (FcγRIIIa V158) to enhance ADCC.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
CAR NK
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic NK-92–derived CAR-NK cells engineered with an anti-CD19 chimeric antigen receptor to recognize and kill CD19+ B cells via NK cytotoxic mechanisms (perforin/granzyme). The cells secrete ER-retained IL-2 to support NK activation and persistence and express high-affinity CD16a (Fc-gamma RIIIa V158) to enhance antibody-dependent cellular cytotoxicity, enabling synergy with therapeutic antibodies.
drug_name
CD19 t-haNK
nct_id_drug_ref
NCT06334991